Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Daniel Lewis Spitz"'
Autor:
Karen Cadoo, Steven C. Plaxe, Janiel M. Cragun, Esteban Rodrigo Imedio, Setsuko K. Chambers, Ganesh Mugundu, Jill J.J. Geenen, Gottfried E. Konecny, Suzanne F. Jones, Lee-may Chen, Tiffany A. Troso-Sandoval, Erika Hamilton, Zhongwu Lai, David R. Spigel, Kathleen N. Moore, Amit M. Oza, Sharad A. Ghamande, Daniel Lewis Spitz, Sanjeev Kumar, Juliann Chmielecki
Publikováno v:
Clinical Cancer Research. 28:36-44
Purpose: This study assessed the efficacy, safety, and pharmacokinetics of adavosertib in combination with four chemotherapy agents commonly used in patients with primary platinum-resistant ovarian cancer. Patients and Methods: Women with histologica
Autor:
Vicky Makker, Jose Alejandro Perez-Fidalgo, Alice Bergamini, Daniel Lewis Spitz, Toon Van Gorp, Jalid Sehouli, Jaroslav Klat, Tamar Perri, Amit M. Oza, Estrid Vilma Solyom Hogdall, Jason A. Konner, Eva M. Guerra, Francesco Raspagliesi, Stephanie Henry, Bradley J. Monk, Jeronimo Martinez Garcia, Brian M. Slomovitz, Sharon Shacham, Mansoor Raza Mirza, Ignace Vergote
Publikováno v:
Journal of Clinical Oncology. 40:5511-5511
5511 Background: Endometrial cancers (ECs) are stratified into four molecular categories: wild type TP53 with non-specific molecular profile typically with microsatellite stability (NSMP, p53wt/MSS), DNA polymerase ε exonuclease domain-mutated (POLE
Autor:
M. Tagliaferri, Linda R. Duska, Daniel Lewis Spitz, U. Hoch, A.L. Hannah, J.P. Micha, J. Bendell, Graham Dark, Nicholas S. Reed, Agustin A. Garcia, Ignace Vergote, G. J. S. Rustin
Publikováno v:
Gynecologic Oncology. 147:276-282
Objective Etirinotecan pegol (EP) is a novel polyethylene glycol conjugated form of irinotecan with documented activity in platinum-resistant ovarian cancer (PROC). We report the results of the expanded portion of a phase II study of EP in patients w
Autor:
Janiel M. Cragun, Erika Hamilton, Lee-may Chen, Juliann Chmielecki, Daniel Lewis Spitz, Jill J.J. Geenen, Zhongwu Lai, Kathleen N. Moore, Amit M. Oza, Suzanne F. Jones, Setsuko K. Chambers, Ganesh Mugundu, Karen Cadoo, Steven C. Plaxe, Gottfried E. Konecny, Tiffany A. Troso-Sandoval, Esteban Rodrigo Imedio, Sharad A. Ghamande, Sanjeev Kumar, David R. Spigel
Publikováno v:
Journal of Clinical Oncology. 37:5513-5513
5513 Background: Adavosertib (AZD1775; A), a highly selective WEE1 inhibitor, demonstrated activity and tolerability in combination with carboplatin (C) in primary PROC. This study (NCT02272790) assessed the objective response rate (ORR) and safety o
Autor:
Paula M. Fracasso, Christine Gennigens, Carol Zhao, Vincent Armenio, Linda Duska, Ignace Vergote, John Micha, Gordon J. S. Rustin, Abraham C. F. Leung, C. H. Pippitt, Agustin A. Garcia, Johanna C. Bendell, Nicholas S. Reed, Daniel Lewis Spitz, Raoudha Soufi-Mahjoubi, Graham Dark, Christopher J. Poole, Luc Y. Dirix, Emad Ibrahim
Publikováno v:
Journal of Clinical Oncology. 31:4060-4066
Purpose Etirinotecan pegol (NKTR-102) is a unique, long-acting topoisomerase-I inhibitor with prolonged systemic exposure to SN38 (7-ethyl-10-hydroxycamptothecin), the active metabolite of irinotecan. This randomized phase II trial investigated two d
Autor:
Maurie Markman, Linda F. Carson, James Hall, Mark E. Baker, Sheldon Weiner, Linda Van Le, Daniel Lewis Spitz
Publikováno v:
Journal of Clinical Oncology. 20:2365-2369
PURPOSE: We wished to critically examine the level of activity of weekly paclitaxel in a patient population with well-characterized platinum/paclitaxel-resistant (3-week schedule) ovarian cancer. PATIENTS AND METHODS: Eligibility criteria for this ph
Autor:
Richard Frank, Fadi Braiteh, Daniel Lewis Spitz, Sarina Anne Piha-Paul, Sudha Parasuraman, J. Thaddeus Beck, Joseph Buscema, Renata M. Matys, Eric Daniel Slosberg, Barinder P. Kang
Publikováno v:
Molecular Cancer Therapeutics. 14:A53-A53
The Signature program comprises a series of 8 tissue-agnostic, mutation-specific protocols without predetermined study sites. Eligible patients have advanced solid and hematologic cancers without remaining standard therapeutic options. Clinical benef
Autor:
Manish Agrawal, Frederick M. Schnell, Vasily J. Assikis, Eric Scott Schaefer, Petros Nikolinakos, Vicki Tosher, Christopher L. Corless, Sibel Blau, Nancy L. Beegle, Stephen G. Divers, Daniel Lewis Spitz, Lindsay Carol Overton, David H. Henry, Marc Chernoff, Colleen Oliver, Dennis Slater, Robert J. Green
Publikováno v:
Journal of Clinical Oncology. 32:11028-11028
11028 Background: Mutational testing has become standard of care in melanoma, lung, and colorectal cancers. The advent of Next Generation Sequencing (NGS) and increasing availability of new targete...
Autor:
Ignace Vergote, Luc Dirix, Linda R. Duska, Carol Zhao, Agustin A. Garcia, G. G. Rao, J. P. Micha, Christine Gennigens, Vincent Armenio, J. West, G. J. S. Rustin, L. K. Masuoka, Daniel Lewis Spitz, C. H. Pippitt, Abraham C. F. Leung, Graham Dark, Christopher J. Poole, Emad Ibrahim, Nicholas S. Reed
Publikováno v:
Journal of Clinical Oncology. 29:5047-5047
5047 Background: NKTR-102, a topoisomerase-I inhibitor-polymer conjugate with markedly reduced peak concentrations and a continuous concentration profile, demonstrated broad antitumor activity per RECIST in a phase I study. The original phase 2 study
Autor:
Nicholas S. Reed, G. G. Rao, D. J. Maslyar, Daniel Lewis Spitz, C. H. Pippitt, Graham Dark, J. P. Micha, Agustin A. Garcia, G. J. S. Rustin, Ignace Vergote
Publikováno v:
Journal of Clinical Oncology. 28:5013-5013
5013 Background: NKTR-102, a topoisomerase I inhibitor-polymer conjugate with reduced peak concentrations and a continuous concentration profile, demonstrated broad antitumor activity based on RECIST criteria in a phase I study, including ovarian can